Dynavax Technologies Corporation (NASDAQ:DVAX) – Cantor Fitzgerald issued their FY2017 earnings per share estimates for Dynavax Technologies Corporation in a note issued to investors on Sunday. Cantor Fitzgerald analyst E. Piros anticipates that the biopharmaceutical company will post earnings per share of ($1.73) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $25.00 target price on the stock. Cantor Fitzgerald also issued estimates for Dynavax Technologies Corporation’s FY2018 earnings at ($1.65) EPS.

Dynavax Technologies Corporation (NASDAQ:DVAX) last posted its earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.15. Dynavax Technologies Corporation had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The business had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.28 million. During the same quarter in the previous year, the firm posted ($0.90) EPS. The firm’s revenue was down 68.8% on a year-over-year basis. TRADEMARK VIOLATION WARNING: This story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/11/15/equities-analysts-issue-forecasts-for-dynavax-technologies-corporations-fy2017-earnings-dvax.html.

A number of other equities research analysts also recently issued reports on the stock. Cowen and Company reissued a “buy” rating and set a $30.00 price objective on shares of Dynavax Technologies Corporation in a research report on Friday, November 3rd. Royal Bank Of Canada reissued an “outperform” rating and set a $28.00 price objective (up previously from $26.00) on shares of Dynavax Technologies Corporation in a research report on Monday, September 25th. ValuEngine raised shares of Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, September 7th. William Blair reissued an “outperform” rating and set a $30.00 price objective on shares of Dynavax Technologies Corporation in a research report on Wednesday, August 9th. Finally, Zacks Investment Research raised shares of Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $25.17.

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) opened at $18.13 on Wednesday. Dynavax Technologies Corporation has a 1 year low of $3.70 and a 1 year high of $24.45.

Several hedge funds have recently modified their holdings of DVAX. Cubist Systematic Strategies LLC boosted its holdings in Dynavax Technologies Corporation by 54.5% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 3,700 shares during the period. Patriot Financial Group Insurance Agency LLC boosted its holdings in Dynavax Technologies Corporation by 16.5% in the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 1,700 shares during the period. Bank of America Corp DE boosted its holdings in Dynavax Technologies Corporation by 2.3% in the 1st quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 456 shares during the period. Legal & General Group Plc boosted its holdings in Dynavax Technologies Corporation by 18.5% in the 2nd quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 1,950 shares during the period. Finally, Wall Street Access Asset Management LLC bought a new position in Dynavax Technologies Corporation in the 2nd quarter worth $124,000. 58.55% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Earnings History and Estimates for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Stock Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related stocks with our FREE daily email newsletter.